A quick update on RRx-001 (for previous info containing preliminary Phase 2 data see: http://coloncancersupport.colonclub.com/viewtopic.php?f=1&t=50662&hilit=rrx+001+trial ).
Although the preliminary Phase 2 data looks encouraging, it is still pending to be seen if it continues to look good in higher patient numbers. I am hoping they will provide a Phase 2 trial clinical update this fall but we'll see........ I am intrigued by this molecule both by the high response rate in the initial small numbers of patients tested as well as the very low side effect profile seen thus far. It appears to resensitize tumors in multiple patients to irinotecan after tumors become resistant.
This week they published in detail their Phase 1 clinical results in the journal "Lancet Oncology". If you are considering this trial, this paper is important for your oncologist to see (along with the preliminary Phase 2 results at the link above) since there is a good chance they have never heard of the molecule. Unfortunately the paper is not free (only the abstract is), costs about $30. http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(15)00089-3.pdf
It is only being tested at a few sites (UCSD, Stanford and I believe if you have a military connection, at Walter Reed on the east coast) and it is randomized 2:1 to receiving Regorafenib, here is the Clinicaltrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02096354?term=rrx-001&rank=5
6/4/2012 Dx Stage 3C CRC @ 40 yo. MSS, KRAS-WT, BRAF-WT, p53-mut
8/13 Enlarged lymphs - Stable
10/14 Stage IV. Lung & Lymph mets. 5-FU+bev
11/15 FOLFIRI + bev
11/16 Signs of FOLFIRI resistance (Lymph mets)
1/17 Palliative radiation for resistant mets
2/17 FOLFIRI + bev + Maraviroc (off-label)
3/17 FOLFIRI + Erbitux + Maraviroc (off-label)MSS-CRC Clinical Trial Finder: http://trialfinder.fightcrc.org/2016 Colondar 2.0 ModelDK37 Science Posts List